Honeycomb Biotechnologies and Revvity launch new solutions to expand the frontiers of single cell research
In collaboration with single cell genomics company, Honeycomb Biotechnologies, Revvity announced the launch of a suite of new solutions and services that expand the frontiers of single cell biology: the HIVE CLX Single-Cell RNAseq Solution, BeeNetPLUS analysis workflow, and for single cell researchers based in the United States, a new HIVE CLX Service offering.
The HIVE CLX Single-Cell RNAseq Solution offers higher density single cell capture with integrated sample storage in an instrument-free workflow.
Honeycomb’s HIVE CLX solution features 160,000 picowells within a single, high-density array that allows for as much as four times as many cells to be recovered per device as compared with the original HIVE scRNAseq Solution.
By eliminating the need for specialized instrumentation, the HIVE CLX solution is well suited to support researchers working in remote or low-resource locations where sample storage and shipping requirements may be more complex. This includes studies involving emerging or evolving infectious diseases like HIV, malaria, tuberculosis and COVID-19, as well as distributed and longitudinal studies that involve multi-point sample collection.
In addition to the HIVE CLX solution, Honeycomb has released its BeeNetPLUS cloud-based analysis workflow that simplifies and accelerates data interpretation of HIVE CLX results. With no coding or command line experience required, the BeeNetPLUS workflow reports on sequencing quality; cell, gene and transcripts recovery; cell-type annotation; differential expression; and marker gene plots.
